Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

  Comunicato Stampa 05-12-2021   Press Release - 2021-05-12


Philogen S.p.A. will announce its maiden First Quarter 2021 Results on Wednesday 12th May 2021

A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021.

Please find the link to this webinar here:

Webinar ID: 826 8156 7012

International numbers available:

  Press Release 06/05/2021



Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs.
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer.

Philogen announces participation to the 10th World Congress of Melanoma
Philogen will give a poster presentation about the phase II study of Daromun (NidlegyTM) for the treatment of non-melanoma skin cancer.

Philogen announces publication of the construction and application of an innovative DNA-encoded chemical library in Nature Chemistry
Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.


  Press Release - 10th World Congress of Melanoma   Press Release - Nature Chemistry   Press Release - PNAS



Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.A

  Press Release 01/02/2021   Comunicato Stampa 01/02/2021



Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma
NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated.
Data Safety Monitoring Board recommends to continue the study as planned.

  Press Release 13/01/2021

By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy